Genologics has been selected by the Sealy Center for Molecular Medicine (SCMM) at the University of Texas Branch at Galveston (UTMB) to collaborate on developing a biomedical software solution.
The SCMM is focused on understanding cell stress response pathways using high-throughput systems-based approaches.
The biomarkers programme is developing new tools to study and classify human diseases at a molecular level, allowing the prediction of individual susceptibility to disease.
This research programme in personalised medicine will allow the centre to make better diagnostics for common medical diseases such as asthma, cancer, diabetes and degenerative diseases.
Dr Allan Brasier, director, SCMM at UTMB, said: 'The Genologics vision to help clients conduct translational research by developing informatics solutions designed for this purpose was completely aligned with the centre's strategic plan to connect our clinical and basic research areas.' Dr Kevin Rosenblatt, director for biomarker discovery at the SCMM, added: 'In order to validate our biomarkers for common diseases, we needed to exchange information from clinical to research domains.
'This can only be done with a biomedical informatics solution that not only tracks our biospecimens, but also the clinical annotations and then connects to the data being generated in our research labs.
'The Genologics Biomedical Informatics solution will have this unique capability to bring it all together in a single platform.' Genologics launched its Biomedical Informatics software solution to address the needs of translational research initiatives.
The solution allows clients to track prospective studies, collect patient data at remote sites, provide biospecimen and clinical annotations management and facilitate researchers querying on clinical information and requesting samples.
The solution is comprised of five integrated products: BioVault for biospecimen management; BioChronicle for clinical annotations management; BioQuest to enable Web access; BioSphere for study management; and BioSource for electronic patient questionnaires.
James DeGreef, vice-president, market strategy for Genologics, said: 'As we develop our new biomedical informatics product suite, it's important to gain the real-world experience of leading organisations such as the SCMM.
'Its input into the design and development of the biospecimen and clinical annotations products will be invaluable, as well as to the deployment of our web query portal as it looks to centralise the management of a number of physically separate biobanks across its research enterprise.'
